Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $79.34, while Zimmer Biomet Holdings Inc trades at $89.54 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares Core MSCI Emerging Markets ETF pays none, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| IEMG | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $107.71 |
52-Week Low | $59.90 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal from moving averages and oscillators. The ETF shows strong recent performance with 35% gains over the past year, driven by emerging market inflows and AI-focused technology exposure. Recent news highlights record capital flows into emerging markets and IEMG's 40% technology weighting, though some analysts caution about elevated volatility and concentration risks.
The outlook remains mixed with attractive emerging market valuations and growth opportunities balanced against geopolitical risks and market volatility. Key catalysts include continued AI-driven technology performance and emerging market economic growth, while risks involve US-China tensions and potential market corrections given the ETF's recent strong run.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
